Friday, February, 21, 2020 12:56:16

Incyte announces results of pivotal Phase 3 GRAVITAS study for GVHD

Incyte, a renowned American biopharmaceutical company reportedly announced the results of Phase 3 GRAVITAS-301 study evaluating itacitinib together with corticosteroids in patients suffering from treatment-naïve acute GVHD (graft-versus-host disease). The results did not reach the primary endpoint of improving ORR (overall response rate) at Day …